Introduction
On circulating platelets, integrin α IIb β 3 is in a resting conformation incapable of binding its ligand fibrinogen (Fg). During platelet activation by physiological agonists, the integrin is rapidly converted to high affinity state through a chain of signaling events termed inside-out signaling. Engagement of activated integrin by Fg transmits signals within the platelet through a cascade termed as outside-in signaling that results in platelet adhesion, spreading, and clot retraction 1 . Integrin activation and signaling is important for the process of hemostasis and thrombosis 2, 3 . Unwanted activation and signaling can result in life-threatening complications. There exists an elaborate mechanism of regulation of agonistdependent integrin affinity modulation to avoid un-instigated activation of integrin.
Likewise, signaling through the integrin (outside-in signaling) is also tightly regulated by both positive and negative regulators. Although a significant amount of information is available regarding the positive regulators, very little is known about the negative regulators 4 .
The mechanism of integrin outside-in signaling in platelets is just beginning to be understood. It has been shown that c-Src, a member of Src family kinases (SFK), plays a significant role in integrin outside-in signaling 3, [5] [6] [7] .
Under resting conditions, SFKs including c-Src are maintained in an inactive state through two intramolecular interactions, including binding of the SH3 domain to a polyproline type II helix, [8] [9] [10] and subsequently binding through its SH2 domain to a phosphotyrosine residue (Y 529 ) in the C-terminal regulatory domain 11 . Maintaining SFKs in an inactive state requires phosphorylation of the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From C-terminal inhibitory Y 529 residue in the SFK by cytoplasmic kinases Csk (Cterminal Src kinase), or Chk (Csk homologous kinase) 12 . It has been shown that Csk suppression of c-Src involves movement of Csk to sites of c-Src activity 13 .
Csk also has a SH2 domain through which it binds to a phosphotyrosine residue in a Csk-binding protein 14 . Previous studies have shown that the adapter protein, Paxillin, can participate in feedback inhibition of nearby SFKs by recruiting Csk 15, 16 . It has also been shown that Hic-5, a member of the Paxillin family, is expressed in human platelets and is tyrosine phosphorylated upon platelet activation. Csk is shown to bind phosphorylated Hic-5 via its SH2 domain 16 . In resting platelets c-Src is constitutively associated with the integrins 17 and is kept in an inactive state by phosphorylation at c-SrcY 529 residue by Csk 7 . However, Hic-5 does not associate with the integrin or regulate c-Src activation. What recruits Csk to the integrin-c-Src complex in inactive platelet is not known.
Cell adhesion molecules belonging to the Ig superfamily have been indicated to exert a negative effect on platelet activation 4 . Junctional adhesion molecule A (JAM-A) is a member of the cortical thymocyte marker of the Xenopus (CTX) family of cell adhesion molecules 18 . JAM-A was originally identified as a platelet receptor for a monoclonal antibody mAb-F11 19 . It has been shown that JAM-A is rapidly phosphorylated during platelet activation by physiological agonists in a PKC-dependent manner 19, 20 . We have recently shown that genetic ablation of murine Jam-A results in a shortened tail bleeding time 21 .
Furthermore, we have shown that loss of Jam-A results in a prothrombotic phenotype as observed by a variety of in vivo thrombosis assays. We showed For personal use only. on October 31, 2017. by guest www.bloodjournal.org From that in Jam-A null murine platelets, inside-out signaling is unaffected, but outsidein signaling is impaired 21 . How JAM-A affects integrin outside-in signaling is not known.
Here we describe the molecular mechanism by which JAM-A regulates integrin outside-in signaling. We found that JAM-A recruits Csk to the integrin α IIb β 3 and c-Src complex in resting platelets, helping in maintaining c-Src in an inactive state. This complex is rapidly dissociated upon platelet activation by agonists followed by dephosphorylation of c-SrcY 529 , which allows the activation of c-Src during integrin outside-in signaling.
For personal use only. on October 31, 2017. by guest the Declaration of Helsinki. Washed human platelets were obtained as described previously 22, 23 . Detail characterization of Jam-A knockout mice (Jam-A gt/gt ) used in this study is reported previously 24, 25 . Approval for animal experimental studies was received from the University of Delaware Institutional Animal Care and Use Committee (IACUC). A heparinized syringe was used to draw blood from the posterior vena cava of 10-14-weeks-old mice and transferred into a tube containing ACD or 3.8% sodium citrate as an anticoagulant depending on the experiment. Mouse blood was diluted using Tyrode's buffer (1:1) in the absence of calcium, and platelet-rich plasma (PRP) was obtained by centrifugation at 200xg for 10 minutes at room temperature (RT) 26 .
Immunofluorescence
Immunofluorescence studies were performed as described previously 27 . In brief, platelet samples were incubated with anti-α IIb and anti-JAM-A for overnight at 4 o C. Samples were then washed and incubated with secondary antibodies; Alexa Fluor® 647 donkey anti-rabbit-conjugated IgG and Alexa Fluor® 568 donkey anti-Mouse IgG. Alexa 488 phalloidin was used to stain F-actin. All samples were mounted in PBS. Using super resolution structured illumination microscope (SIM) ELYRA PS.1 (Carl Zeiss, Ithaca, NY), SIM z-stacks were acquired with 5 rotations and 5 phase shifts using a 100x α -Plan-Apochromat (NA = 1.46) oil immersion medium objective lens. Images were captured using an iXon 885 back-thinned EM-CCD camera (Andor Technology PLC, Belfast, Northern Ireland). SIM reconstructions were performed using an experimental point spread function, baseline cutoff processing and an affine image alignment based on a multi-speck bead alignment. Images were acquired and adjusted in Zen 2011 software (Carl Zeiss, Ithaca, NY).
Cell culture and transfection
Dami, a human megakaryocytic cell line (ATCC; Manassas, VA) were transfected with mock (empty vector pcDNA 3.1), or full length JAM-A or JAM-A Y280F mutant constructs using Lipofectamine 2000 (Invitrogen) as described 27, 28 . The level of protein expression was determined by immunoblotting.
Immunoprecipitation
Immunoprecipitation studies were performed using human platelets (4x10 8 /mL) or mouse platelets (2x10 8 /mL) as described previously 29 . In brief, non-tissue culture petri dishes were coated with Fg (100μg/mL) or 3% BSA for 1hour at 37 o C and then blocked with 0.5% heat-inactivated BSA. Washed mouse or human platelets (1ml per dish) pretreated with apyrase (1U/ml) and aspirin (1mM) were allowed to spread on Fg or BSA pre-coated dishes for 60 minutes (for human platelets) and 90 minutes (for murine platelets) at 37 o C. In a separate set of experiments, platelets were pretreated with RGDS or EDTA prior to stimulation with thrombin. For artificial activation of the integrin, platelets in suspension were treated with Mn 2+ in the absence or presence of Fg. For time course experiments, platelets in suspensions were activated by 20μM ADP or 10μg/mL collagen at 0, 1, 3 and 5 minutes. Platelets were lysed using ice-cold lysis buffer (1%NP-40, 150mM NaCl and 50mM Tris-HCl pH 7.5, containing 10μg/mL each of leupeptin, levisole, and aprotinin; 1mM each of phenylmethylsulfonylfluoride, NaF, and sodium orthovanadate; 0.2% deoxycholate). Lysates were pre-cleared by incubating with IgG followed by protein G-Sepharose beads for 30 minutes. Pre-cleared lysates were incubated with the indicated primary antibody or isotype-specific IgG as a control for 1hour at RT followed by incubation with protein G-Sepharose beads for overnight at 4 o C. In the integrin αIIb or β 3 immunoprecipitation experiments, pre-cleared lysates were incubated with the indicated primary antibody or isotype-specific IgG for overnight at 4 o C, centrifuged for 30 seconds and the supernatant was incubated with protein A-Sepharose beads (GE, Piscataway, NJ) for 1hour at RT.
Immunocomplex beads were washed 3X with lysis buffer in the absence of inhibitors and immediately boiled in 2X Laemmli-sample buffer and processed for immunoblotting.
Immunoblotting
Proteins from the lysates or immunoprecipitates were separated by 8% or 10% SDS-PAGE under reducing conditions and transferred to PVDF membrane. After transfer the blots were blocked with 3% BSA and incubated with primary antibody as indicated for overnight followed by incubation with the appropriate secondary antibody at RT for 1hour. The bands were visualized by chemiluminescence using Lumiglo® substrate (Cell Signaling, Danvers, MA). Blots were stripped and reprobed with the appropriate primary antibody followed by secondary antibody to determine the total amount of protein in the immunoprecipitates. Quantification of band intensity was performed using Gel doc software (BioRad, Hercules, CA).
GST-pull-down assay
GST-pull-down assay was performed as described previously 16 . In brief, a cDNA insert corresponding to Csk-SH2 domain was subcloned into pGEX4T-1 vector (GE). The in-frame ligation was confirmed by DNA sequencing. For expression of GST-fusion proteins, IPTG-induced bacterial cells were lysed using French press. The lysates were incubated with glutathione beads and the thoroughly washed beads were used as needed. Lysates of washed human platelets (2x10 8 /mL) stimulated with AYPGKF (PAR4 peptide) or unstimulated were incubated with GST-beads or GST-Csk-SH2 domain fusion protein-beads for overnight at 4 o C. In order to avoid distortion of JAM-A band, by the GST-SH2 fusion protein (which runs at the same place as JAM-A on SDS-PAGE), the washed beads were further incubated with thrombin (1U) for 10 minutes at RT to cleave fusion protein and immediately boiled in the presence of 2X Laemmlisample buffer and processed for immunoblotting.
Platelet aggregation:
Platelet aggregation was performed using a Chrono-Log lumi-aggregometer (Chrono-Log) as described previously 26 . Aggregation curves were recorded using Aggrolink software (Chrono-Log).
Statistical analysis
Statistical analysis of the data was performed using Student's t-test (mean +SEM value; SEM, standard error of the mean). P< 0.05 is regarded as statistically significant. Each experiment was repeated at least three times independently using different blood donors or set of mice.
Results

JAM-A associates with resting integrin α
We have recently shown that JAM-A protects from thrombosis by suppressing integrin α IIb β 3 outside-in signaling 21 . It is therefore possible that JAM-A may exert this inhibitory effect by physically associating with the integrin. To test this possibility, we immunoprecipitated JAM-A from lysates of resting and thrombin stimulated human platelets and tested for the presence of the integrin α IIb β 3 in the immunoprecipitate by immunoblotting. Isotype-specific IgG was used as a negative control. We first tested if the activation of platelets by thrombin affected the protein levels in the lysates. We found an equal amount of candidate proteins present in both resting and activated platelet lysates ( Figure 1A ). We found that a significant amount of integrin α IIb β 3 was coimmunoprecipitated with JAM-A from resting platelet lysates, but it was absent from the lysates of platelets stimulated by thrombin ( Figure 1B&C ). Similar results were obtained when washed platelets were exposed to BSA or immobilized Fg. A significant amount of integrin α IIb β 3 was coimmunoprecipitated with JAM-A from platelet lysates exposed to BSA, but negligible amount from the lysates of platelets exposed to Fg ( Figure 1D&E ). In order to determine if this association was specific, we evaluated if GPIb, a major platelet surface protein, is present in the JAM-A immunoprecipitate. We found a complete absence of GPIb in JAM-A immunoprecipitate from both resting and thrombin activated platelet lysates, suggesting that the observed interaction between JAM-A and integrin α IIb β 3 is highly specific ( Figure 1F ). In order to confirm the association of JAM-A from the integrin and its dissociation upon platelet activation, we performed the time course of dissociation upon activation of platelets by other physiological agonists such as ADP and collagen ( Figure   1G ). We found that, JAM-A time-dependently dissociates from the integrin upon activation of platelets by both strong as well as mild agonists. When analyzed by super resolution immunofluorescence microscopy, we found that integrin α IIb β 3 and JAM-A co-localized on the membrane of resting platelets exposed to BSA.
Upon platelet spreading on immobilized Fg, a significant amount of JAM-A moved towards the center of the platelet thus reducing the amount of colocalization with the integrin at the membrane ( Figure 1H ). These results suggest that JAM-A associates with the integrin α IIb β 3 in the resting confirmation and dissociates from the integrin once the integrin is activated. In order to determine whether the dissociation of JAM-A from the integrin is dependent on integrin activation (inside-out signaling) or ligand-dependent outside-in signaling, we performed association studies in the absence of ligand binding (presence of RGDS or EGTA). We found no dissociation of JAM-A from the integrin when ligand binding is blocked ( Figure 1I ). Furthermore, we also performed artificial activation of the integrin using Mn +2 . We found that artificial activation and ligand occupancy of the integrin is enough to dissociate JAM-A from the integrin ( Figure   1I ).
Integrin α IIb β 3 associated JAM-A is tyrosine phosphorylated.
JAM-A is phosphorylated on tyrosine residue in its cytoplasmic domain 30 and this phosphorylation is important for its function in endothelial cells 31 . To test if the tyrosine phosphorylation is altered during its dissociation from the integrin, we immunoprecipitated integrin α IIb β 3 and determined the tyrosine phosphorylation state of the coimmunoprecipitated JAM-A by immunoblotting using 4G10, a phosphotyrosine-specific antibody. As expected, we found that JAM-A is associated with the integrin α IIb β 3 only under resting conditions and this integrin associated JAM-A was tyrosine phosphorylated, which was absent in the integrin immunoprecipitate from activated platelet lysates ( Figure 2A&B ). However, it does not prove that JAM-A is dephosphorylated upon platelet activation. To determine if the JAM-A that is dissociated from the integrin is tyrosine phosphorylated, we immunoprecipitated JAM-A from platelet lysates exposed to Fg or BSA and determined its tyrosine phosphorylated status. We found that in platelets exposed to BSA JAM-A was phosphorylated on the tyrosine residue.
However, JAM-A was almost completely dephosphorylated upon exposure to Fg ( Figure 2C&D ). These results suggest that tyrosine phosphorylated JAM-A and resting integrin α IIb β 3 form a complex, which was dissociated upon ligand binding to the activated integrin and possibly dephosphorylation of JAM-A.
Loss of Jam-A results in activation-dependent enhanced c-Src activation in murine platelets.
Since loss of Jam-A augments integrin α IIb β 3 signaling in platelets 21 , we hypothesized that c-Src, a downstream tyrosine kinase activated during outsidein signaling may be activated in the absence of Jam-A. To test this, we immunoprecipitated c-Src from lysates of Jam-A wt/wt and Jam-A gt/gt platelets exposed to immobilized BSA or Fg and assessed the Y 418 phosphorylation of c-Src, a measure of c-Src activation. We found that c-Src Y 418 phosphorylation was minimal in both Jam-A wt/wt and Jam-A gt/gt mouse platelets exposed to BSA ( Figure   3A&B ). However, c-Src is phosphorylated on Y 418 in Jam-A wt/wt platelets exposed to Fg and this phosphorylation is significantly augmented in Jam-A gt/gt platelets exposed to Fg ( Figure 3A&B ) suggesting that adhesion-dependent integrin outside-in signaling is required for c-Src activation and that the presence of Jam-A suppresses c-Src activation as indicated by increased Y 418 phosphorylation in its absence.
Phosphorylation of c-Src Y529 does not occur in the absence of Jam-A.
It is known that c-Src is maintained in unactivated state by multiple intra phosphorylation. To test this, we immunoprecipitated integrin α IIb β 3 from lysates of Jam-A wt/wt and Jam-A gt/gt platelets exposed to BSA or Fg to obtain integrin associated c-Src. We next analyzed the state of Y 529 phosphorylation of this integrin-associated c-Src. We found that a comparable amount of c-Src was coimmunoprecipitated from each lysates ( Figure 3C ). As expected in Jam-A wt/wt platelets exposed to BSA almost all integrin-associated c-Src was phosphorylated on Y 529 , which was significantly reduced upon exposure of Jam-A wt/wt platelets to Fg ( Figure 3C&D ). Interestingly, Y 529 phosphorylation in Jam-A gt/gt platelets exposed to both BSA and Fg was significantly attenuated compared to Jam-A wt/wt platelets ( Figure 3C&D) . These results suggest that Jam-A is needed for the efficient phosphorylation of c-Src on Y 529 residue.
We have previously reported that loss of Jam-A on platelets results in a gain of function as indicated by hyperaggregation of platelets to physiological agonists 21 . Our results presented thus far suggest that loss of Jam-A promotes c-Src activation. It is therefore plausible that observed gain of function could be due to enhanced c-Src activation and that pharmacological inhibition of c-Src activation should rescue this phenotype in Jam-A gt/gt platelets. To test this, we performed ADP-induced platelet aggregation assays using Jam-A wt/wt and Jam-A gt/gt platelets pretreated with PP2, a well-characterized inhibitor of c-Src 33 .
DMSO was used as a vehicle control. As previously reported, we found hyperaggregation in the Jam-A gt/gt platelets compared to Jam-A wt/wt ( Figure   3E&F ). Pretreatment with PP2 attenuated ADP induced aggregation response in both Jam-A wt/wt and Jam-A gt/gt platelets. Interestingly, the gain of function seen in Jam-A gt/gt platelets was completely rescued by PP2 ( Figure 3E&F ). These results suggest that Jam-A exerts its pro-aggregatory effect by suppressing c-Src activation.
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JAM-A associates with Csk in the resting platelets
It has been well documented that Csk is responsible for the Y 529 phosphorylation of c-Src in resting platelets 7 . Furthermore, Csk has been shown to be associated with the integrin-c-Src complex in resting platelets 7 . What recruits Csk to this complex is, however, not known. We reasoned that JAM-A may be a Cskbinding protein and is responsible for the recruitment of Csk to the integrin complex. To test this, we immunoprecipitated JAM-A from the lysates of resting or thrombin-activated human platelets and immunoblotted for Csk. We found that a significant amount of Csk was associated with JAM-A in resting platelets, which dissociated upon platelet activation ( Figure 4A&B ). To test if this dissociation is outside-in signaling-dependent, we immunoprecipitated JAM-A from the lysates of human platelets pretreated with aspirin, to block TxA2 generation and apyrase to quench any secreted ADP followed by exposure of these platelets to immobilized BSA or Fg.
We found that JAM-A coimmunoprecipitated Csk from BSA exposed platelet lysates, but not from Fg exposed platelet lysates ( Figure 4C&D ). These results suggest that Csk associates with JAM-A in resting platelets and dissociates during outside-in signaling.
Csk associates with tyrosine phosphorylated JAM-A through its SH2domain.
In resting platelets, JAM-A is tyrosine phosphorylated and binds to Csk; it is therefore reasonable to speculate that tyrosine phosphorylation of JAM-A may be necessary for its ability to bind Csk. We therefore determined if the tyrosine phosphorylation of JAM-A is necessary for this interaction. We transfected wild type and Y 280 F mutant JAM-A in Dami cells and co-immunoprecipitation of Csk with JAM-A was assessed in resting cells. We found that a significant amount of Csk was associated with wild type JAM-A, but not with Y 280 F mutant of JAM-A, although similar amount of JAM-A was immunoprecipitated in each conditions ( Figure 5A&B ). These results suggested that phosphorylated Y 280 residue in JAM-A is important for the association of Csk. We next asked if this tyrosine residue is also important for the interaction of JAM-A with the integrin since dephosphorylated JAM-A was not seen associating with the integrin.
Interestingly, the Y 280 F mutation did not affect the ability of JAM-A to associate with the integrin in Dami cells, suggesting that tyrosine phosphorylation is not required for the interaction of JAM-A with the integrin (Figure 5C&D ).
Csk has a SH2 domain through which it can bind to phosphotyrosine residues of the binding proteins 14 . To test if the SH2 domain of Csk is capable of interacting with JAM-A, we used GST-fusion protein expressing SH2 domain of Csk to pull-down JAM-A from lysates of resting or platelets stimulated with PAR4-peptide. We found that a significantly higher amount of JAM-A was pulled down by SH2-GST fusion protein from resting platelets as compared to activated For personal use only. on October 31, 2017. by guest www.bloodjournal.org From platelets ( Figure 5E&F ). GST beads alone did not pull-down any JAM-A, suggesting the specificity of the pull-down assay. To test if outside-in signaling will affect this association, we repeated the pull-down assay using lysates of aspirin and apyrase treated platelets exposed to immobilized BSA or Fg. We found that a substantial amount of JAM-A was specifically pulled down by SH2fusion protein from lysates of platelets exposed to BSA ( Figure 5G ). GST without the SH2 domain did not pull-down JAM-A. Furthermore, SH2-fusion protein failed to pull-down significant amount of JAM-A from platelets exposed to Fg ( Figure   5H ). These results collectively suggest that Csk associates with Y 280 phosphorylated JAM-A through its SH2 domain in resting platelets and platelet activation dissociates this complex probably due to dephosphorylation of JAM-A.
JAM-A recruits Csk to the integrin complex.
In order to conclusively determine if JAM-A is the only protein that is responsible for recruiting Csk to the integrin α IIb β 3 complex in platelets, we immunoprecipitated integrin α IIb β 3 from lysates of resting Jam-A wt/wt and Jam-A gt/gt mouse platelets using both anti-α IIb and anti-β 3 antibodies. Isotype-specific IgG was used as control. Immunoprecipitates were analyzed for the presence of Csk by immunoblotting. We found that both the integrin subunit specific antibodies co-immunoprecipitated significant amount of Csk from Jam-A wt/wt platelet lysates ( Figure 6A,B,&C) . However, Csk was completely absent in the immunoprecipitates from Jam-A gt/gt platelets. The faint ghost band seen in Jam-A gt/gt platelet lysates is the IgG heavy chain, which is also evident in the control IgG lane (Figure 6A ). These results strongly suggest that Jam-A is the protein responsible for the recruitment of Csk to the integrin α IIb β 3 -c-Src complex in resting platelets.
We conclude that JAM-A discourages sporadically activated integrin from propagating outside-in signaling by attenuating c-Src activation. This is achieved by association with the integrin and by recruiting a signaling molecule, Csk, which is known to exert an inhibitory constrain on outside-in signaling. In For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Discussion
It has been well documented that affinity modulation of integrin is carefully regulated in platelets 3, 35, 36 . Our results show that there also exists an intricate control of integrin signaling. We show that JAM-A is responsible for suppressing integrin outside-in signaling. Similar to JAM-A, several other CAM family members notably PECAM-1, CEACAM1, and ESAM have also been implicated to suppress platelet activation albeit through different mechanisms. PECAM-1, which contains an ITIM and an ITSM motif, is rapidly tyrosine phosphorylated upon platelet activation 37 . Phosphorylated PECAM-1 binds phosphatase SHP1 and SHP2 and inhibits inside-out signaling induced by GPVI 37,38 . However, ablation of PECAM-1 impairs integrin outside-in signaling such as clot retraction, platelet spreading on immobilized Fg, and tyrosine phosphorylation, suggesting that PECAM-1 supports integrin outside-in signaling [39] [40] [41] . CEACAM1 also an ITIM containing protein negatively regulates platelet functions induced through GPVI signaling 42 . Additionally, G6B, another ITIM containing orphan receptor expressed on platelets, was also shown to exert inhibitory effect on GPVIinduced platelet function, probably via recruitment of SHP1 and SHP2 43, 44 . In contrast, JAM-A does not contain ITIM or ITSM motifs, is constitutively phosphorylated on tyrosine, and is rapidly dephosphorylated upon platelet activation. Furthermore, ablation of JAM-A results in faster clot retraction and platelet spreading as well as increased integrin tyrosine phosphorylation 21 .
ESAM, another CAM family member closely related to JAM-A (both belonging to the CTX subfamily), has also been shown to be a suppressor of platelet function with a difference. Although ablation of ESAM results in a gain-offunction similar to JAM-A, integrin outside-in signaling as assessed by clot retraction is impaired in the absence of ESAM which is opposite in case of JAM-A 45 .
Our finding that JAM-A associates with integrin α IIb β 3 in resting platelets and its dissociation from the integrin upon platelet activation provides a mechanistic role for its function. Interestingly, we and others have shown that JAM-A associate with integrin α v β 3 on quiescent endothelial cells and similar to platelets, it dissociates from the integrin upon activation of endothelial cells by growth factors or cytokines 28, 31, 46 . Furthermore, it has recently been shown that the association of JAM-A with the integrin α v β 3 on endothelial cells is via CD9 46 .
Since platelets abundantly express CD9, it is possible that JAM-A associates with integrin α IIb β 3 via CD9 in platelets as well.
Our identification of JAM-A as the Csk-binding protein provides a molecular mechanism of regulation of integrin-dependent c-Src activation in platelets. The identity of JAM-A as the Csk-binding protein is supported by the study of Ford et al., where they showed an unknown 36 kDa protein being the Csk-binding protein in human megakaryocytic cell line 47 . This molecular size matches well with JAM-A and JAM-A is also expressed abundantly in these cells.
Paxillin and its family member, Hic-5, have been shown to function as Cskbinding proteins 16 . However, they bind SFKs other than c-Src. Also, they function to restrict feedback inhibition of SFKs by sequestering Csk away from c-Src.
It is known that c-Src can become partially activated (primed) simply by binding to the β3 integrin tail through its SH3 domain 34 
